1/12
07:00 am
tara
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Medium
Report
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
1/9
06:10 am
tara
Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Low
Report
Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
1/7
08:10 am
tara
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support [Yahoo! Finance]
Medium
Report
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support [Yahoo! Finance]
1/7
08:00 am
tara
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/7
08:00 am
tara
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
Medium
Report
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
1/7
06:05 am
tara
Protara Therapeutics (NASDAQ:TARA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Protara Therapeutics (NASDAQ:TARA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/5
08:06 am
tara
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
Medium
Report
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
1/5
08:00 am
tara
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Medium
Report
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
12/8
04:05 pm
tara
Protara Announces Closing of $75 Million Public Offering
Low
Report
Protara Announces Closing of $75 Million Public Offering
12/4
11:50 pm
tara
Protara Announces Pricing of $75 Million Public Offering [Yahoo! Finance]
Medium
Report
Protara Announces Pricing of $75 Million Public Offering [Yahoo! Finance]
12/4
10:03 pm
tara
Protara Announces Pricing of $75 Million Public Offering
Medium
Report
Protara Announces Pricing of $75 Million Public Offering
12/4
04:57 pm
tara
Protara Announces Proposed Public Offering [Yahoo! Finance]
Medium
Report
Protara Announces Proposed Public Offering [Yahoo! Finance]
12/4
04:15 pm
tara
Protara Announces Proposed Public Offering
High
Report
Protara Announces Proposed Public Offering
12/4
07:33 am
tara
Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]
Medium
Report
Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]
12/3
02:19 pm
tara
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Low
Report
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
12/3
08:00 am
tara
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Medium
Report
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
12/1
05:32 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 [Yahoo! Finance]
High
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 [Yahoo! Finance]
12/1
04:15 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
High
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
11/19
12:08 pm
tara
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Medium
Report
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
11/19
08:00 am
tara
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Low
Report
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
11/18
04:57 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 [Yahoo! Finance]
Low
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 [Yahoo! Finance]
11/18
04:30 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
Low
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
11/17
08:00 am
tara
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
Low
Report
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
11/10
08:00 am
tara
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
High
Report
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
11/4
04:05 pm
tara
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
Low
Report
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace